Verastem (NASDAQ: VSTM)
Verastem Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Verastem Company Info
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
News & Analysis
Why Verastem Stock Spiked Today
A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today.
Why Verastem Stock Is Crushing It Today
The biotech's experimental cancer treatment won an important regulatory designation today.
Why Verastem Stock Sank Today
The biotech's chief medical officer has stepped down just two weeks after joining the company.
Why Verastem Stock Jumped Briefly This Morning
The biotech company reported second-quarter earnings and sold some drug development rights.
Why Verastem Stock Is Rising Today
If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.
Here's Why Verastem Oncology Is Tanking Today
Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.
3 Top Stocks Under $5 to Buy Now
Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.
Top Drug Stocks Under $5
Healthcare bargain hunters can find good values in quality low-priced stocks.
Valuation
Earnings Transcripts
Verastem Inc (VSTM) Q2 2019 Earnings Call Transcript
VSTM earnings call for the period ending June 30, 2019.
Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript
VSTM earnings call for the period ending March 31, 2019.
Verastem (VSTM) Q4 2018 Earnings Conference Call Transcript
VSTM earnings call for the period ending December 31, 2018.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.